Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Alessandro Cerri, Oliver Fairhurst and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Simone Lorenzi and Asude Sena Moya.
Results for Rose Hughes
No change: The EPO's guidance to Examiners on how to apply G1/24 No change: The EPO's guidance to Examiners on how to apply G1/24 Reviewed by Dr Rose Hughes on Friday, August 01, 2025 Rating: 5
BREAKING: Referral on description amendments finally confirmed! (G1/25 - "Hydroponics") BREAKING: Referral on description amendments finally confirmed! (G1/25 - "Hydroponics") Reviewed by Dr Rose Hughes on Tuesday, July 29, 2025 Rating: 5
G 1/24 in the spotlight: Description definitions do not override clear claim language (T 1999/23) G 1/24 in the spotlight: Description definitions do not override clear claim language (T 1999/23) Reviewed by Dr Rose Hughes on Thursday, July 24, 2025 Rating: 5
Why patents matter: Understanding the importance of IP in the pharma industry Why patents matter: Understanding the importance of IP in the pharma industry Reviewed by Dr Rose Hughes on Wednesday, July 23, 2025 Rating: 5
Peas and the peculiarities of product-by-process patents (T 1065/23) Peas and the peculiarities of product-by-process patents (T 1065/23) Reviewed by Dr Rose Hughes on Friday, July 18, 2025 Rating: 5
UK IPO launches SEPs consultation UK IPO launches SEPs consultation Reviewed by Dr Rose Hughes on Tuesday, July 15, 2025 Rating: 5
First interpretation of G 1/24 (the description must always be consulted) (T 1561/23) First interpretation of G 1/24 (the description must always be consulted) (T 1561/23) Reviewed by Dr Rose Hughes on Friday, July 11, 2025 Rating: 5
Pitfalls of cell therapy manufacturing IP - A case study (T 0868/23) Pitfalls of cell therapy manufacturing IP - A case study (T 0868/23) Reviewed by Dr Rose Hughes on Monday, July 07, 2025 Rating: 5
Non-reproducible commercial products are prior art (G1/23) Non-reproducible commercial products are prior art (G1/23) Reviewed by Dr Rose Hughes on Friday, July 04, 2025 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.